Unraveling the role of fibroblasts, FGF5 and FGFR2 in HER2-targeted therapies resistance and tumor progression

The majority of women with HER2-positive breast cancer will initially respond to trastuzumab and/or other HER2-targeted therapies such as pertuzumab, lapatinib, neratinib and trastuzumab emtansine (T-DM1). However [...].

Detalles Bibliográficos
Autores: Bragado, Paloma, Fernández-Nogueira, Patricia, Carbó Carbó, Neus, Gascón, Pere
Tipo de recurso: artículo
Estado:Versión publicada
Fecha de publicación:2020
País:España
Institución:Universidad de Barcelona
Repositorio:Dipòsit Digital de la UB
OAI Identifier:oai:diposit.ub.edu:2445/175915
Acceso en línea:https://hdl.handle.net/2445/175915
Access Level:acceso abierto
Palabra clave:Fibroblasts
Càncer
Cancer
id ES_8ef1d6e4e99192377d8ffd27ff83cf59
oai_identifier_str oai:diposit.ub.edu:2445/175915
network_acronym_str ES
network_name_str España
repository_id_str
spelling Unraveling the role of fibroblasts, FGF5 and FGFR2 in HER2-targeted therapies resistance and tumor progressionBragado, PalomaFernández-Nogueira, PatriciaCarbó Carbó, NeusGascón, PereFibroblastsCàncerFibroblastsCancerThe majority of women with HER2-positive breast cancer will initially respond to trastuzumab and/or other HER2-targeted therapies such as pertuzumab, lapatinib, neratinib and trastuzumab emtansine (T-DM1). However [...].Impact Journals2020info:eu-repo/semantics/articleinfo:eu-repo/semantics/publishedVersionapplication/pdfhttps://hdl.handle.net/2445/175915Articles publicats en revistes (Bioquímica i Biomedicina Molecular)reponame:Dipòsit Digital de la UBinstname:Universidad de BarcelonaInglésReproducció del document publicat a: https://doi.org/10.18632/oncotarget.27829Oncotarget, 2020, vol. 11, num. 49, p. 4541-4543https://doi.org/10.18632/oncotarget.27829cc-by (c) Bragado, Paloma et al., 2020http://creativecommons.org/licenses/by/3.0/esinfo:eu-repo/semantics/openAccessoai:diposit.ub.edu:2445/1759152026-05-27T06:46:51Z
dc.title.none.fl_str_mv Unraveling the role of fibroblasts, FGF5 and FGFR2 in HER2-targeted therapies resistance and tumor progression
title Unraveling the role of fibroblasts, FGF5 and FGFR2 in HER2-targeted therapies resistance and tumor progression
spellingShingle Unraveling the role of fibroblasts, FGF5 and FGFR2 in HER2-targeted therapies resistance and tumor progression
Bragado, Paloma
Fibroblasts
Càncer
Fibroblasts
Cancer
title_short Unraveling the role of fibroblasts, FGF5 and FGFR2 in HER2-targeted therapies resistance and tumor progression
title_full Unraveling the role of fibroblasts, FGF5 and FGFR2 in HER2-targeted therapies resistance and tumor progression
title_fullStr Unraveling the role of fibroblasts, FGF5 and FGFR2 in HER2-targeted therapies resistance and tumor progression
title_full_unstemmed Unraveling the role of fibroblasts, FGF5 and FGFR2 in HER2-targeted therapies resistance and tumor progression
title_sort Unraveling the role of fibroblasts, FGF5 and FGFR2 in HER2-targeted therapies resistance and tumor progression
dc.creator.none.fl_str_mv Bragado, Paloma
Fernández-Nogueira, Patricia
Carbó Carbó, Neus
Gascón, Pere
author Bragado, Paloma
author_facet Bragado, Paloma
Fernández-Nogueira, Patricia
Carbó Carbó, Neus
Gascón, Pere
author_role author
author2 Fernández-Nogueira, Patricia
Carbó Carbó, Neus
Gascón, Pere
author2_role author
author
author
dc.subject.none.fl_str_mv Fibroblasts
Càncer
Fibroblasts
Cancer
topic Fibroblasts
Càncer
Fibroblasts
Cancer
description The majority of women with HER2-positive breast cancer will initially respond to trastuzumab and/or other HER2-targeted therapies such as pertuzumab, lapatinib, neratinib and trastuzumab emtansine (T-DM1). However [...].
publishDate 2020
dc.date.none.fl_str_mv 2020
dc.type.none.fl_str_mv info:eu-repo/semantics/article
info:eu-repo/semantics/publishedVersion
format article
status_str publishedVersion
dc.identifier.none.fl_str_mv https://hdl.handle.net/2445/175915
url https://hdl.handle.net/2445/175915
dc.language.none.fl_str_mv Inglés
language_invalid_str_mv Inglés
dc.relation.none.fl_str_mv Reproducció del document publicat a: https://doi.org/10.18632/oncotarget.27829
Oncotarget, 2020, vol. 11, num. 49, p. 4541-4543
https://doi.org/10.18632/oncotarget.27829
dc.rights.none.fl_str_mv cc-by (c) Bragado, Paloma et al., 2020
http://creativecommons.org/licenses/by/3.0/es
info:eu-repo/semantics/openAccess
rights_invalid_str_mv cc-by (c) Bragado, Paloma et al., 2020
http://creativecommons.org/licenses/by/3.0/es
eu_rights_str_mv openAccess
dc.format.none.fl_str_mv application/pdf
dc.publisher.none.fl_str_mv Impact Journals
publisher.none.fl_str_mv Impact Journals
dc.source.none.fl_str_mv Articles publicats en revistes (Bioquímica i Biomedicina Molecular)
reponame:Dipòsit Digital de la UB
instname:Universidad de Barcelona
instname_str Universidad de Barcelona
reponame_str Dipòsit Digital de la UB
collection Dipòsit Digital de la UB
repository.name.fl_str_mv
repository.mail.fl_str_mv
_version_ 1869413170690392064
score 15.300719

Similares en LA Referencia